Article Information
History
- September 21, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Ritthideach Yorsaenga,
- Nungruthai Suntronwonga,
- Harit Phowatthanasathiana,
- Suvichada Assawakosria,
- Sitthichai Kanokudoma,
- Thanunrat Thongmeea,
- Preeyaporn Vichaiwattanaa,
- Chompoonut Auphimaia,
- Lakkhana Wongsrisanga,
- Donchida Srimuana,
- Thaksaporn Thatsanatorna,
- Sirapa Klinfuenga,
- Natthinee Sudhinaraseta,
- Nasamon Wanlapakorna and
- Yong Poovorawana,b,*
- aCenter of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
- bFRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok 10330, Thailand
- ↵*Corresponding author: Yong Poovorawan, M.D., Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. E-mail: yong.p{at}chula.ac.th
Posted September 21, 2021.
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
